Eli Lilly Presents P-III (ADvocate 1 & 2) Trial Results of Lebrikizumab for the Treatment of Atopic Dermatitis at EADV 2022
Shots:
- The P-III (ADvocate 1 & 2) trial evaluating lebrikizumab (250mg, q2w, or q4w) as monothx. in adult & adolescent patients aged 12 to ≤18yrs. with AD
- The results showed a robust & durable improvement in skin clearance & itch who achieved a clinical response @16wk. through 1yr. of treatment, patients treated with lebrikizumab (250mg, q4w & q2w) achieved IGA (0,1) & ≥2 point improvement (74% & 76%) in (ADvocate 1) trial & (81% & 65%) in (ADvocate 2) trial; EASI-75 (79% & 79%) & (85% & 77%); pruritus NRS ≥4-point improvement (80% & 81%) & (88% & 90%)
- The results were consistent with prior studies, AEs (58% & 68%) & the results will be published in a peer-reviewed journal. The regulatory submission of lebrikizumab is expected to be planned in 2022 for the US & EU
Ref: Eli Lilly | Image: Eli Lilly
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.